Sevuparin

Drug Profile

Sevuparin

Alternative Names: DF-02; LAH - Modus Therapeutics; Low anticoagulant heparin - Modus Therapeutics

Latest Information Update: 22 Feb 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Dilafor
  • Developer Arabian Gulf University; Mahidol Oxford Tropical Medicine Research Unit; Modus Therapeutics
  • Class Anticoagulants; Antimalarials; Antithrombotics; Heparins; Low molecular weight heparins
  • Mechanism of Action Cell adhesion molecule inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sickle cell anaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Falciparum malaria; Sickle cell anaemia

Most Recent Events

  • 22 Feb 2017 Modus Therapeutics plans clinical trials for Sickle cell anaemia (Modus Therapeutics pipeline, February 2017)
  • 03 Dec 2016 Pharmacodynamics data from a phase II trial in Sickle cell anaemia (In adolescents, In adults) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology (ASH-2016)
  • 16 Feb 2016 Dilaforette enter into a clinical collaboration agreement with Arabian Gulf University for Sevuparin in Sickle cell anaemia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top